Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/24/2026 | $30.00 | Outperform | Wedbush |
| 4/24/2026 | $46.00 | Outperform | Leerink Partners |
| 4/23/2026 | $31.00 | Overweight | Analyst |
| 4/22/2026 | $40.00 | Overweight | Barclays |
| 4/21/2026 | $45.00 | Buy | UBS |
Wedbush initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $30.00
Leerink Partners initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $46.00
Analyst initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $31.00
3 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
SCHEDULE 13G - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)